active healthy feel great finally like carol willis annual report mission clear discover develop deliver innovative medicine help patient prevail disease sense urgency real work day push boundary scientific discovery meaningful difference live patient commit develop century workforce powerfully diverse broadly inclusive capable discover develop important new medicine patient world patient story share annual report depict individual patient response medicine investigational compound representative patient response addition guarantee potential drug indication development receive regulatory approvalat bristolmyer squibb employee like mina chaudhry austin thekkumthala passionate turn scientific insight new therapeutic option patient need bristolmyer squibb annual report bristolmyer squibb look forward exciting future build strong foundation grow business help patient great medicine great people giovanni caforio chairman board chief executive officer bristolmyer squibb come work day highly competitive market opdivo approve mission mind discover develop deliver transformational tumor type indication opdivo revenue grow medicine help patient face disease percent end year billion global sale opdivo continue maintain grow market share approve indication expand new tumor early performance strong company create line therapy see significant growth launch great momentum business expand indication opdivo adjuvant treatment melanoma approval oncology portfolio important approval opdivo opdivo plus lowdose yervoy treatment line rcc plus lowdose yervoy treatment renal cell carcinoma additionally opdivo plus lowdose yervoy approve rcc europe reach important milestone european medicine agency line rcc january eliquis take leadership position prevention expand immunooncology combination stroke patient atrial fibrillation advance broad therapy treatment option patient rcc market deep pipeline oncology cardiovascular disease fibrosis europe immunoscience continue effort good global citizen green initiative invest opdivo distinguish immunooncology therapy local community support need approve china milestone tribute focus effort team china ensure speed result deliver important medicine cancer patient china mark outstanding commercial execution end year billion revenue percent global sale increase growth nearly priority medicine result translate directly medicine deliver patient strong operating performance europe result gaap earning share united nongaap earning share represent state yearoveryear growth percent transform cancer care remain priority company focus increase survival rate patient great rest range tumor type oncology franchise perform world troper launna bbiuqs sreymlotsirb opdivo growth priority delivering brand medicine billion revenue eliquis orencia patient revenue growth yervoy empliciti eliquis continue grow internationally significant progress advance revenue total billion represent percent innovative medicine pipeline include clinical program increase achieve major milestone immunoscience fibrosis cardiovascular disease result new prescription eliquis surpass warfarin phase study selective tyk inhibitor treatment previous standard care stroke prevention atrial fibrillation moderate severe plaque psoriasis publish new number prescribe oral anticoagulant england journal medicine september registrational eliquis continue lead novel oral trial indication underway continue advance anticoagulant globally stroke prevention patient fibrosis portfolio lead compound area fgf atrial fibrillation treatment nonalcoholic steatohepatitis nash currently enrol phase trial heart failure research eliquis clinical profile support continued nitroxyl donor asset currently phase trial look investment realworld datum analysis publish forward datum readout come year additionally acropolis apixaban experience realworld sign collaboration agreement janssen pharmaceutical population study study include development factor xia inhibitor secondary million patient record large body realworld stroke prevention initiate phase trial evidence existence analyze effectiveness safety anticoagulant include eliquis patient nonvalvular broad development program oncology include atrial fibrillation venous thromboembolism important grow body work translational medicine give great insight patient benefit proud medicine discover develop medicine open new research center bristolmyer squibb scientist receive cambridge massachusetts focus resistance treatment prestigious sir james black award british current immunooncology agent look forward pharmacological society contribution discovery leverage rich scientific ecosystem location drive eliquis innovation field deliver tomorrow clinical program focus expand benefit immunooncology portfolio move early line scientist bristolmyer squibb understand urgent therapy include adjuvant setting follow surgery need patient new treatment option hard work prevent recurrence generation transformational medicine patient continue invest research development new expect number datum readout lung treatment option address significant unmet medical need cancer program study opdivo treatment bristolmyer squibb annual reportpage global diversity inclusion people business resource group people business resource group pbrg leverage diverse experience perspective employee drive transformative business result total pbrg membership unique member glioblastoma head neck liver renal deliver underserved cancer start begin chapter community result study adjuvant treatment bring great understanding role year bristolmyer squibb opdivo early stage disease foundation continue build capacity include result adjuvant melanoma bladder expand access care underserve esophageal cancer year result population support innovative program present tumor renal liver lung train health care provider mobilize cancer come subsequent year community fight disease innovation focus believe effort include extensive program country tomorrow medicine come remove barrier increase internal effort rich access specialized care vulnerable ecosystem scientific innovation exist population improve lung cancer awareness outside company business care support reintegration development team hard work find return veteran family medicine year enter include significant innovation access global strategic collaboration jointly develop cardiovascular care commercialize nektar therapeutic bristolmyers squibb foundation lead immunooncology program nktr combination opdivo opdivo work bring quality cancer treatment plus yervoy nektar program provide african community focus cervical bristolmyer squibb validate lung cancer southern east africa mechanism immunooncology provide pediatric cancer southern east africa cultivate leadership innovation opportunity build experience west africa leverage extensive millennial opdivo yervoy learning year secure future program large private january announce definitive initiative address hiv aids southern merger agreement plan acquisition east africa foundation work celgene corporation transaction community partner promote cancer create lead focus specialty biopharma screening train healthcare provider company position address lesbian gay bisexual transgender ally change outcome cancer patient need patient cancer inflammatory follow launch project echo immunologic disease cardiovascular cancer foundation funding disease highvalue innovative expansion telementore program medicine lead scientific capability rural hospital south africa complementary area focus combine company operate global recognize helping improve access reach scale maintain speed medicine critical importance agility core company strategic ensure patient benefit innovation approach bristolmyer squibb patient transaction subject approval bristolmyers squibb celgene shareholder satisfaction customary closing condition regulatory approval bristolmyer squibb celgene expect complete transaction quarter troper launna bbiuqs sreymlotsirbas regain strength carol resume favorite activity woodworke passion share uncle jerry patient story build fight carol willi active healthy feel great finally like april carol willi certain patient advance retired school teacher renal cell carcinoma rcc oakdale mother kidney cancer spread grown child experience initial develop nagging cough effect excellent discover mass response opdivo right yervoy combination recall carol notice remission carol lose weight difficulty clean scan january focus thought easily fatigue show mass active healthy daughter nurse practitioner feel great finally like immediately see urologist say scan get sick change prioritie carol say fam selfdescribe private person ily close generation leave grand doctor confirm daughter madelyn mother vivian carol daughter mindy carol enjoy quiet life style kidney cancer say resume specialist tell stage renal cell carcinoma hobby woodworking travel spend soon surgery remove large tumor time child grandchild texas followup appointment doctor explain colorado despite surgery carol cancer spread lung past year opportunity meet liver point refer oncologist speak number bristolmyer squibb employee principal investigator clinical trial carol say hear personal story know say passionate help patient enter clinical trial investigate opdivo skill dedication combination treatment yervoy enjoy life bristolmyer squibb annual report bristolmyer squibb achievement assistance foundation uninsured patient face financial hardship able obtain medicine need respect integrity quality fight disease work commitment good citizenship extend medicine community impact natural disaster year bring great pride devastation wildfire california hurricanes north carolina grateful florida flood landslide japan earthquake recognition receive include tsunami indonesia bristolmyers squibb foundation respond quickly cash donation disaster relief partner provide essential supply company donate muchneede product year perfect help impact community score corporate equality index cei continue work united nations global compact green activity bristolmyer squibb site promote sustainability environmental program recognize rank topscore energy star partner year sustain excellence award company disability consecutive year effort improve energy efficiency equality index facility worldwide dow jones north strengthen company culture american index lead sustainable company bristolmyer squibb well bright people fuel success hard work commitment second year row able realize mission help patient fight disease careerbliss happy company america commit create sustain strong culture inclusion foster highly innovative work environment people business resource group pbrg leverage diverse experience perspective employee drive transformative business work mother result member pan asian network partner good company organization china launch global buddy system design consecutive year mentor colleague new clinical development china result accelerated launch opdivo additionally lgbta pbrg introduce bestoftheb set transgender guideline ensure respectful corporation inclusion inclusive workplace environment employee process national business inclusion gender transition consortium embed culture deep commitment integrity uncompromise ethic work ensure high ethic military friendly company integrity foundation showcase powerful effective military program look forward workplace bristolmyer squibb look forward exciting future build strong foundation grow business cr good corporate citizen bestcorporate help patient great medicine great people citizen consecutive year focus patient family demand good people possibility endless continue create value patient shareholder employee forbe capital excite future company america thank energy star partner year sustain excellence award giovanni caforio chairman board chief executive officer rank pharmaceutical company innovation quality april management nafe company executive woman troper launna bbiuqs sreymlotsirb patient story experience benefit ken simpson benefit receive eliquis great peace mind ability continue live life love one ken simpson nationally rank cardiologist continue high school american swimmer checked periodically earn athletic year pass ken condition scholarship university illinois gradually worsen mid year cardiologist remove blood college graduation clot leave anterior experience heart problem descend artery fortunate come survive procedure year year later daylong spend entire business career business meeting chicago wrigley company ken grateful second chance consider find walk train chicago ken say day lucky reconnecte childhood station stop work feel strange feeling chest sweetheart beverly year apart time know go know wha know right station obvious wrong wrigley family separately own chicago cub baseball emergency room ekg identify ken condition team time ken send team doctor familiar diagnose atrial fibrillation type irregular work accomplish athlete prescribe heart heartbeat cause heart valve problem cardiologist monitor wear month irregularity find immediately prescribe eliquis reduce increase risk stroke patient ken condition face late ken begin swim national master swimming program adult competition strange eliquis religiously morning night feel chest return sure miss dose ken say flutter skip heartbeat like thunderous nowretire businessperson say sell steady heartbeat explain decide go live benefit product advice life afraid heart condition apparently sell successfully diagnose swam race win time get matter product important pool strange heartbeat go benefit provide user ken say benefit heart monitor show irregularity ken receive eliquis great peace mind convince wrong begin see ability continue live life love one bristolmyers squibb annual reportbristolmyer squibb development portfolio therapeutic area oncology phase phase phase iii approve indication opdivo opdivo opdivo opdivo solid tumor crc glioblastoma braf wildtype metastatic hematologic malignancy melanoma nonhodgkin lymphoma hcc opdivo yervoy diffuse large bcell adjuvant melanoma head neck lymphoma solid tumor advance hodgkin lymphoma head neck locally nonhodgkin lymphoma relatlimab advanced melanoma braf status follicular lymphoma solid tumor esophageal mesothelioma ovarian hematologic malignancy adjuvant bladder previously treat advanced pan tumor tmb high nlrp agonist rcc adjuvant esophageal pediatric solid tumor gastroesophageal previously treat gastric primary testicular cancer jpn antitim adjuvant gastric lymphoma previously treat hcc solid tumor adjuvant hcc opdivo previously treat metastatic humaxil adjuvant rcc solid tumor head neck solid tumor nsclc neoadjuvant opdivo yervoy previously treat metastatic antagonist refractory hodgkin melanoma prostate lymphoma solid tumor previously treat metastatic opdivo yervoy unresectable nsclc msihigh crc cdcd oncolytic solid tumor virus opdivo yervoy previously treat metastatic relatlimab opdivo nonsquamous nsclc solid tumor bladder solid tumor previously treat metastatic antictla probody esophageal squamous nsclc ido opdivo solid tumor gastric previously treat metastatic solid tumor antiicos head neck sclc nktr opdivo solid tumor mesothelioma previously treat metastatic solid tumor urothelial antictla nsclc ccr dual antagonist opdivo yervoy solid tumor sclc solid tumor rcc antitigit adjuvant melanoma cabiralizumab braf wildtype metastatic solid tumor adjuvant rcc melanoma solid tumor anticd nsclc egfr mutant melanoma braf status solid tumor opdivo yervoy previously treat metastatic cabozantinib bet inhibitor msihigh crc metastatic rcc solid tumor yervoy opdivo empliciti ulocuplumab adjuvant melanoma multiple myeloma hematologic malignancy adolescent metastatic opdivo ido melanoma metastatic melanoma metastatic melanoma neoadjuvant muscle empliciti invasive bladder cancer relapsedrefractory multiple opdivo nktr myeloma pomalyst combo melanoma relapsedrefractory multiple myeloma revlimid combo line rcc line relatlimab opdivo sprycel cml chronic myelogenous leukemia cml crc colorectal cancer melanoma hcc hepatocellular carcinoma empliciti pediatric nsclc nonsmall cell lung cancer refractory cml rcc renal cell carcinoma multiple myeloma sclc small cell lung cancer revlimid combo troper launna bbiuqs sreymlotsirbbristolmyers squibb development portfolio therapeutic area immunoscience phase phase phase iii approve indication rort tyk inhibitor orencia orencia autoimmune disease autoimmune disease idiopathic inflammatory early rheumatoid arthritis myopathy agonist btk inhibitor juvenile idiopathic sjgren disease arthritis intravenous autoimmune disease rheumatoid arthritis tyk inhibitor juvenile idiopathic btk max arthritis subcutaneous psoriasis rheumatoid arthritis psoriatic arthritis nulojix tyk inhibitor rheumatoid arthritis switch autoimmune disease auto injector calcineurin inhibitor tlr antagonist renal transplant rheumatoid arthritis intravenous autoimmune disease rheumatoid arthritis subcutaneous nulojix novo renal transplant cardiovascular phase phase phase iii approve indication fpr agonist nitroxyl donor eliquis eliquis heart failure heart failure pediatric venous stroke prevention thromboembolism atrial fibrillation apj agonist factor xia inhibitor prevention venous thromboembolism heart failure thrombosis prevention orthopedic eliquis surgery pediatric heart disease venous thromboembolism treatment fibrotic disease phase phase lpa antagonist hsp fibrosis fibrosis pegbelfermin pegfgf nonalcoholic steatohepatitis note pipeline exclude clinical collaboration trial explore combination partnerrun study development partnership opdivo yervoy relatlimab ono collaboration ono include early stage compound empliciti abbvie nktr nektar cabiralizumab prime cabozantinib exelixis eliquis pfizer factor xla inhibitor janssen hsp nitto denko pomalyst revlimid trademark celgene corporation list table investigational compound clinical study approve potential indication market product relate therapeutic area january list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound bristolmyers squibb annual report secure future anniversary inception secure future oversaw investment million program train year ago world prepare ten thousand health care provider increase capacity care welcome new millennium hospital clinic raise awareness hiv prevention million people live hivaid increase communitybased support child family virus third million affect disease people country subsaharan africa secure future impact pediatric care landmark woman child initiative bring foundation bipai transmission rate subsaharan country rise government subsaharan country botswana lesotho access adequate care low world resource eswatini uganda tanzania create large pediatric hiv extremely limited hivaid lead treatment network world date bipai treat cause death threaten region future million child currently directly care global pharmaceutical company strong portfolio percent teenager adolescent hiv therapie bristolmyer squibb take major role today secure future focus evolve help address fight disease african continent major health challenge cancer people bristolmyers squibb foundation company launch hiv living long die virus secure future groundbreake commitment noncommunicable disease hypertension cancer help transform healthcare deliver region secure future create partnership base year collaboration partnership government experience hiv address lung cervical breast international agency include world health pediatric cancer blood disorder organization unaid baylor international pediatric aids bipai texas childrens hospital cancer hematology initiative bipai nongovernmental community center bristolmyers squibb foundation launch global faith base organization secure future create hope hematologyoncology pediatric excellence model care hiv sustainable comprehensive program treat child cancer blood replicate applied disease area disorder hiv disparitie cancer care africa start secure future look part world significant pediatric cancer build local national capacity help inform country survival rate percent compare mortality rate high hivaid plan develop lesson experience percent africa address health disparity woman child secure future innovate model care therapeutic area say john damonti delivery building capacity local african health professional president bristolmyers squibb foundation care treat child woman lifethreatene disease partnership program help restore hope say phangisile mtshali director bristolmyers squibb foundation child family live hivaid give lesson learn extended reach subsaharan community subsaharan africa confidence africa create communitybased treatment support program resource need properly care patient helped deliver antiretroviral therapy rural hardtoreach area partnership global programme influential shaping policy practice monitor report community effort find miss tuberculosis case take lesson learn apply address pediatric lung cervical cancer rob africa bright future gain hiv success troper launna bbiuqs sreymlotsirb secure future anniversary leg acy hope bristolmyers squibb annual report patient story day live jessie stern faith prayer strength day live jessie stern drive home candidate immuno car rearende stop sign oncology therapy jessie doctor follow weekend jessie prescribed opdivo retire mother grandmother month receive harrisburg begin feel treatment jessie begin pain abdomen visit improvement tumor local emergency room receive shrink examination include mri xray late set jessie scan come clear detectable turn sign cancer physically wrong car accident jessie smoker selfdescribe people person past year say doctor jessie admits struggle noticed abnormality depression learn jessie friend deborah fight lung look scan provide strength hope laughter way cancer stay strong try schedule biopsy specialist positive say say stage iii lung cancer say prayer get jessie suffer nonsmall cell lung cancer nsclc today exercise gym watch diet common type lung cancer make past share story cancer patient percent case accord national cancer institute support group oncologist office believe well hear deal cancer jessie treat chemotherapy radiation experience treatment work second chemotherapy try jessie like way treatment feel jessie feel good look forward future ask stop treatment oncologist suggest look cancer faith prayer strength say different option biopsy doctor determine day live troper launna bbiuqs sreymlotsirbbristolmyers squibb financial report management discussion analysis financial condition result operation quantitative qualitative disclosure market risk consolidated financial statement note consolidated financial statement report management control procedure report independent register public accounting firm performance graph year financial summary summary abbreviate term board director leadership team stockholder information bristolmyer squibb management discussion analysis financial condition result operation executive summary bristolmyers squibb company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end term document receive approval new medicine additional indication formulation currently market medicine major market japan china include multiple regulatory milestone achievement opdivo opdivoyervoy combination commit investigate opdivo combination yervoy anticancer agent wide array tumor type include broad program lung head neck liver kidney bladder stomach continue believe breadth depth portfolio position future new compound clinical development study different tumor type addition advance certain nonio programs pipeline include tyk inhibitor treatment psoriasis autoimmune disease factor xia inhibitor treatment thrombosis collaboration janssen pegbelfermin pegfgf treatment nash revenue increase result high demand prioritize brand include opdivo eliquis partially offset increase competition establish brand primarily hiv brands daklinza increase gaap ep primarily tax charge attribute tax reform high revenue item partially offset high loss equity investment adjust impact tax reform equity investment loss specify item nongaap eps increase primarily result high revenue high royalty license income low effective tax rate cost saving result transformation initiative continue redeploy area high priority january announce enter definitive merger agreement celgene acquire celgene discussion pende acquisition celgene acquisition divestitures license arrangement refer consolidated financial statementsnote acquisition divestitures license arrangement note subsequent event revenue increase result high demand prioritize brand include opdivo eliquis partially offset increase competition establish brand primarily daklinza decrease gaap ep tax charge attribute tax reform share less extent high license asset acquisition restructuring relate charge low divestiture relate income item partially offset high revenue royalty licensing income patentinfringement settlement adjust impact tax reform specify item nongaap eps increase primarily result high revenue partially offset product mix high expense support opdivo program highlight follow table summarize financial information year end december dollar million share datum total revenue dilute earning share gaap nongaap nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure annual report significant product pipeline approval follow summary significant approval receive product date approval august approval japan patient mpm progress chemotherapy august approval japan adjuvant treatment melanoma fda approval treatment option patient metastatic sclc august cancer progress platinumbase chemotherapy line therapy opdivo approval adjuvant treatment adult patient melanoma involvement july lymph nodes metastatic disease undergo complete resection approval china treatment locally advanced metastatic nsclc prior june platinumbase chemotherapy adult patient egfr alk genomic tumor aberration approval japan opdivo plus lowdose yervoy treatment unresectable august metastatic rcc fda approval opdivo plus lowdose yervoy treatment adult pediatric july patient year old msih dmmr mcrc progress follow opdivoyervoy treatment fluoropyrimidine oxaliplatin irinotecan approval japan opdivoyervoy combination previously untreated patient unresectable melanoma fda approval opdivoyervoy combination previously untreated patient april intermediate poorrisk advanced rcc approval japan intravenously administer treatment moderate severe orencia february polyarticular jia patient year age old fda approval empliciti injection intravenous use combination pomalidomide empliciti november dexamethasone treatment adult patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor fda expand indication sprycel include treatment pediatric patient december year age old newly diagnose philadelphia chromosomepositive combination chemotherapy sprycel expand indication sprycel include treatment child adolescent july aged year year chronic phase philadelphia chromosomepositive cml include powder oral suspension approval advance unresectable metastatic melanoma pediatric patient yervoy january year age old refer product pipeline development development market product latestage pipeline early bristolmyer squibb strategy focus specialty biopharmaceutical company discover develop deliver transformational medicine address unmet medical need strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry strategic priority drive business performance continue build lead franchise maintain diversified portfolio outside continue discipline approach capital allocation include establish partnership collaboration inlicense acquire investigational compound essential component successfully deliver transformational medicine patient develop new medicine follow core therapeutic area oncology priority certain tumor type immunoscience prioritie psoriasis lupus inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priority lung liver continue advance wave innovative medicine invest significantly pipeline internally business development activity expect plan acquisition celgene position lead biopharmaceutical company expand oncology immunoscience portfolio nearterm asset additional external partnership continue invest portfolio pursue monotherapy combination approach advance wave early asset enter new collaboration agreement therapeutic area focus expand research develop opdivo approve investigational oncology agent combination regimen remain focused wellresourced cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave mechanism develop treatment option refractory patient cancer continue advance early stage portfolio immunoscience cardiovascular fibrotic disease strengthen partnership diverse group company academic institution new expand research activity believe differentiate internal external focus contribute advance pipeline potentially transformational medicine commercial model evolve revenue prioritize brand continue grow demonstrate strong execution strategy continue drive growth opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent eliquis continue grow leverage good class clinical profile extensive real world datum number novel oral anticoagulant total prescription build continue success prioritize brand remain strongly commit orencia sprycel operating model transformation commercial infrastructure uniquely leverage potential growth operating model continue evolve successful focus commercial manufacturing resource prioritize brand market strengthen capability tumor biology patient selection new biomarker deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio evolution operating model focus maintain discipline approach marketing sell administrative expense enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio look ahead continue implement biopharma strategy drive growth prioritize brand execute product launch invest diverse innovative pipeline aid strategic business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition divestiture license collaboration arrangement acquisition divestiture license collaboration arrangement allow focus resource growth opportunity drive great longterm value focus follow core therapeutic area oncology include immunoscience cardiovascular fibrosis significant acquisition divestiture license collaboration arrangement past year summarize refer consolidated financial statementsnote alliance note acquisition divestiture license arrangement information arrangement nektar bms nektar commence worldwide license collaboration development commercialization nktr nektars investigational immunostimulatory therapy janssen bms janssen commence worldwide collaboration development commercialization factor xia program include bmss factor xia inhibitor bms investigational anticoagulant compound study prevention treatment major thrombotic condition annual report promedior bms notify promedior company exercise warrant obtain purchase outstanding share promedior rigel bms notify rigel pharmaceuticals inc company discontinue participation preclinical collaboration cancer immunotherapy base rigel small molecule tgf beta receptor kinase inhibitor originally commence bavarian nordic bms notify bavarian nordic company exercise option globally license commercialize prostvac bavarian nordics investigational psatargeting cancer immunotherapy arrangement ono bms acquire exclusive license develop commercialize ono onos prostaglandin receptor antagonist treatment cancer bm acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms medicine halozyme enhanze drugdelivery technology allow rapid delivery large volume injectable medication ifm bms acquire outstanding share ifm provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy cytomx bms cytomx expand initial strategic collaboration discover novel cancer treatment therapy include additional target cytomxs proprietary probody platform treatment cancer arrangement psioxus bms acquire exclusive worldwide right psioxus preclinical stage armed oncolytic virus goal address solid tumor padlock bms acquire outstanding share padlock provide bms right padlock pad inhibitor discovery program focus development treatment approach patient cormorant bms acquire outstanding share cormorant provide bms right cormorant lead candidate humaxil monoclonal antibody represent potentially complementary mechanism action tcell direct antibodie costimulatory molecules nitto denko bms acquire exclusive worldwide license develop commercialize nitto denko investigational sirna molecule target heat shock protein hsp vitamin contain formulation include nitto denko lead asset ndls currently development treatment advance liver fibrosis option receive exclusive license hsp sirnas vitamin contain formulation treatment lung organ fibrosis bristolmyer squibb result operation regional revenue composition change revenue follow year end december total revenue analysis change analysis change total foreign total foreign dollar million change exchangeb change exchangeb united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period sale revenue impact high demand opdivo eliquis partially offset low demand establish brand increase competition primarily hiv brand daklinza high growth rate additional indication approval opdivo average net selling price unchanged chargeback rebate discount refer product revenue commentary additional information europe revenue impact high demand eliquis opdivo foreign exchange partially offset low demand establish brand increase competition low average net selling price rest world revenue impact low demand establish brand increase competition low average net selling price foreign exchange partially offset high demand opdivo eliquis revenue impact high demand eliquis opdivo partially offset low demand establish brand increase competition primarily daklinza hiv brand average net selling price approximately high chargeback rebate discount refer product revenue commentary additional information europe revenue impact high demand opdivo eliquis partially offset low demand daklinza increase competition low average net selling price rest world revenue impact low demand establish brand include daklinza increase competition outlicense mature brand product partially offset high demand opdivo eliquis low average net selling price single country outside contribute total revenue annual report gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy activity end reserve balance significant category gtn adjustment follow rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january provision relate sale current period prior period payment return foreign currency translation balance december provision relate sale current period prior period payment return assetsrelate liability heldforsale foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow year end december change dollar million gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment increase high rate gross product sale high eliquis gross product sale relatively high gtn adjustment percentage result competitive pressure maintain position healthcare payer formulary allow patient continue access medical plan bristolmyer squibb product revenue year end december change dollar million prioritize brand opdivo nonus eliquis nonus orencia nonus sprycel nonus yervoy nonus empliciti nonus establish brand baraclude nonus reyataz franchise nonus sustiva franchise nonus hepatitis franchise nonus brand nonus total revenue nonus change excess annual report opdivo nivolumab fully human monoclonal antibody bind nkt cell approve anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach continues investigate tumor type disease area revenue increase period high demand high growth rate primarily approval treatment adjuvant melanoma liver cancer opdivoyervoy combination kidney cancer partially offset decline lung cancer indication international revenue increase period high demand result approval additional indication launch new country low growth rate primarily additional competition opdivo nsclc indication eliquis apixaban oral factor inhibitor target stroke prevention adult patient nvaf prevention treatment vte disorder revenue increase period market share gain partially offset low average net selling price international revenue increase period high demand attribute market share gain growth novel oral anticoagulant market orencia abatacept fusion protein indicate adult patient moderate severe active psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia revenues increase period high demand high average net selling price international revenue increase period high demand experience additional competition europe biosimilar competitor product future period sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate revenue decrease inventory workdown offset high average net selling price revenue increase high demand high average net selling price international revenue remain unchanged international revenue increase high demand experience decline european revenue event generic datasinib product enter market yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase period high demand revenue growth rate decrease low demand result product adjuvant treatment patient melanoma include opdivo international revenue increase period high demand primarily europe follow approval opdivo yervoy combination therapy melanoma baraclude entecavir oral antiviral agent treatment chronic hepatitis international revenue decrease period low demand result increase competition reyataz atazanavir sulfate franchise include reyataz protease inhibitor treatment hiv evotaz atazanavir cobicistat combination therapy contain reyataz tybost cobicistat loe reyataz occur december result revenue continue decline international revenue decrease period low demand result increase competition sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla loe sustiva occur december gilead terminate bms participation canada joint venture follow launch generic version sustiva result bms share atripla revenue decline year refer consolidated financial statementsnote alliance discussion international revenue include million atripla royalty revenue bristolmyers squibb hepatitis franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir protease inhibitor beclabuvir nsb inhibitor international revenue decrease period low demand result increase competition brand include brand include lose exclusivity major market otc brand royalty revenue international revenue decrease primarily low plavix royalty result adoption amend revenue guidance expiration right abilify canada low diabete product supply sale continue generic erosion revenue decrease outlicense divestiture certain brand continue generic erosion estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate december daklinza month inventory hand result minimum require stock level support patient demand expect inventory hand level daklinza exceed month near term international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france efferalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france fervex cold flu product month inventory hand direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france daklinza hepatitis product month inventory hand internationally direct customer compare month inventory hand june level inventory hand attributable low volume inmarket sale canada perfalgan analgesic product month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily gulf country extend delivery lead time sustiva hiv product month inventory hand internationally direct customer compare month inventory hand june level inventory hand attributable low volume inmarket sale canada generally determine month hand estimate inventory level product hand movement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process annual report nonus business significantly direct customer information available direct customer product level inventory correspond outmovement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer party market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior filing disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative research development income net total expense cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share certain excise taxis foreign currency hedge settlement gain loss amortization acquire develop technology cost cost product sell typically vary period result product mix volume particularly royaltie profit share less extent change foreign currency price inflation cost attribute manufacturing site exit cost product sell increase high royalty profit share million result primarily high eliquis sale partially offset product cost improvement million impairment charge reduce carry value small molecule active pharmaceutical ingredient manufacturing operation sword ireland low inventory charge cost product sell increase high royalty profit share million result primarily high eliquis sale million impairment charge discuss remain increase primarily high sale volume inventory charge manufacture startup cost foreign currency marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement expense typically vary period new product launch promotional activity marketing sell administrative expense decrease low advertising promotion marketing expense low cost attribute transformation initiative lower brand prescription drug fee partially offset high bms foundation grant marketing sell administrative expense decrease low advertising promotion salesforce expense support daklinza establish brand low bms foundation grant bristolmyers squibb research development research development activity include discovery research preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense decrease low site exit cost iprd impairment charge partially offset expansion opdivo development program include nktr research development expense increase high license asset acquisition charge site exit charge iprd impairment charge expansion opdivo development program significant charge include expense follow year end december dollar millions nektar cormorant ifm cytomx halozyme flexus cardioxyl psioxus ono padlock nitto denko license asset acquisition charge fstar iprd impairment site exit cost research development significant charge upfront payment milestone payment license asset acquisition charge result strategic transaction acquire license certain investigational oncology cardiovascular immunoscience fibrotic disease compound option acquire license disclose acquisition divestiture license collaboration arrangement iprd impairment charge include discontinue development investigational compound alliance fstar site exit cost result expect exit site primarily reduction estimate useful life relate asset impairment charge reduce carry value facility wallingford connecticut annual report income net income net decrease primarily loss equity investment relate nektar patent infringement settlement partially offset low restructure debt redemption charge income net increase primarily patent infringement settlement outlicense income partially offset low divestiture gain relate service fee high restructure debt redemption charge component income net follow year end december dollar million interest expense investment income lossgain equity investment provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investment include fair value adjustment million relate company equity investment nektar restructuring charge relate change company operating model drive continue success near longterm focus investment commercial opportunity key brand market competitive agile organization accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability reflect current future portfolio streamline simplify smallmolecule supply network new operating model expect enable company deliver strategic financial operational flexibility necessary invest high priority company aggregate restructuring charge million million incur respectively action include accelerate depreciation impairment charge result early site exit litigation settlement include million bms share patentinfringement settlement relate merck antibody keytruda million relate intellectual property product liability settlement include million recognize subsequent company earning release fourth quarter divestiture gain include divestiture multiple mature global product line oncology infectious therapy additional contingent consideration diabete business certain otc brand investigational hiv medicine business royalty licensing income include keytruda royalty upfront licensing fee biogen roche connection outlicense certain investigational genetically define disease compound contingent consideration erbitux diabetes business divestiture including transfer certain royalty right pertaining diabete product sale million fee amend royalty rate million salesbase milestone include transition service fee include fee result divestiture diabete investigational hiv medicine business pension postretirement include interest cost expect return plan asset amortization component net periodic benefit cost credit net charge settlement curtailment special termination benefit million million million intangible asset impairment include million outlicense asset obtain acquisition zymogenetics inc meet primary endpoint phase clinical study debt redemption loss million result early redemption certain longterm debt obligation bristolmyer squibb income taxis dollar million earning income taxis provision income taxis effective tax rate impact specify item change effective tax rate primarily new tax reform legislation know tax cut job act act enact december act move worldwide tax system quasiterritorial tax system comprise broad complex change tax code include limited reduce tax rate add deem repatriation transition tax certain foreign earning profit generally eliminate federal income taxis dividend foreign subsidiary include certain income control foreign company taxable income gilti create new minimum tax refer base erosion antiabuse income tax limit certain researchbase credit eliminate domestic manufacturing deduction aspect act effective additional tax expense billion recognize fourth quarter enactment act additional expense increase effective tax rate include billion time deem repatriation transition tax previously untaxe post foreign earning profit include related tax reserve earning effectively tax rate extent specify foreign corporation hold cash certain asset rate remain earning profit remain million additional tax expense include adjustment measure net defer tax asset new tax rate accounting reduction defer tax asset tax rate complete december provisional tax charge deem repatriation transition tax reduce million completion accounting reduce effective tax rate addition tax impact attribute specify item include nondeductible charge valuation allowance certain tax asset result equity investment loss jurisdiction tax rate increase effective tax rate consider impact specify item include transitional impact act discuss effective tax rate decrease primarily ongoing impact act tax reserve release partially offset taxis attribute internal cash repatriation earning mix high low tax jurisdiction consider impact specify item effective tax rate decrease primarily adoption amend income tax accounting guidance relate share base payment early adoption intraentity transfer asset inventory partially offset earning mix high low tax jurisdiction refer consolidated financial statementsnote income taxis information nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include restructuring cost accelerate depreciation impairment property plant equipment intangible asset charge connection acquisition licensing thirdparty intellectual property right divestiture gain loss pension legal contractual settlement charge debt redemption gain loss item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understanding underlie financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap annual report specify item follow year end december dollar million impairment charge accelerate depreciation shutdown cost cost product sell marketing sell administrative license asset acquisition charge iprd impairment site exit cost research development lossgain equity investmentsa provision restructure litigation settlement divestiture gain royalty license income pension postretirement intangible asset impairment loss debt redemption income net increase pretax income income taxis item income taxis attribute tax reform income taxis increase net earning noncontrolle interest increase net earning diluted nongaap eps calculation specify item include amount adoption amend guidance recognition measurement financial asset liability reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap bristolmyers squibb financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm debt obligation longterm debt net cash position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily international affiliate local operating need subject onetime deem repatriation transition tax billion payable year result tax reform expect flexibility access cash future cash generate foreign subsidiary believe exist cash cash equivalent marketable security cash generate operation issuance commercial paper sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment working capital deem repatriation transition tax billion debt mature management continuously evaluate company capital structure ensure company finance efficiently result repurchase common stock debt security termination interest rate swap contract prior maturity issuance debt security average commercial paper outstanding million weightedaverage rate maximum commercial paper outstanding million outstanding borrowing december dividend payment billion billion dividend decision quarterly basis board director annual capital expenditure approximately billion billion billion expect approximately million million continue expand biologic manufacturing capability facilityrelate activity example construct new largescale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio approve commercial use early pay billion nektar certain collaboration right million share common stock represent ownership interest investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer consolidated financial statementsnote financial instrument fair value measurement information december revolve credit facility total billion consist day billion facility schedule expire march fiveyear billion facility extend september july respectively facility provide customary term condition financial covenant billion revolving facility extendable annually year anniversary date consent lender borrowing outstanding revolve facility december connection pende acquisition celgene january enter bridge commitment letter provide billion day senior unsecured bridge loan facility enter billion term loan credit agreement consist billion day tranche billion threeyear tranche billion fiveyear tranche term loan reduce commitment bridge facility billion obtain additional funding issue security obtain loan bridge facility correspondingly reduce bridge loan term loan subject customary term condition financial covenant amount borrow bridge loan term loan prior close pende acquisition celgene january enter new revolve credit facility total billion day billion facility expire january threeyear billion facility expire january day billion facility replace exist day billion revolving facility terminate concurrently effectiveness new day facility support commercial paper borrowing facility provide customary term condition financial covenant annual report borrowing outstanding revolve facility billion revolve facility february follow announcement pende acquisition celgene enter forward start interest rate swap option contract swaption total notional value billion hedge future interest rate risk associate anticipate issuance longterm debt fund acquisition swaption provide right enter forward start interest rate swap contract period year january additional regulation pass future include additional healthcare reform initiative change tax law additional pricing law potential importation restriction reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer believe economic condition material impact liquidity cash flow financial flexibility vote depart june similar company industry certain regulatory trade labor aspect business likely affect time currently believe matter relate financial effect material impact consolidate result operation financial position liquidity sale represent consolidate revenue credit rating january moody place bms review downgrade standard poor place bms creditwatch negative implication follow announcement acquire celgene bms current longterm shortterm credit rating assign moody investor service prime respectively bms current longterm shortterm credit rating assign standard poor respectively longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally current longterm shortterm rating reflect impact propose acquisition celgene cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business example annual employee bonus typically pay quarter subsequent year addition cash collection continue impact long payment term certain biologic product primarily new oncology product include opdivo yervoy empliciti day day long payment term closely align insurance reimbursement time physician cancer center follow administration patient bristolmyer squibb million change cash flow operating activity compare primarily attributable high cash collection time payment ordinary course business approximately billion partially offset high licensing collaboration payment approximately million primarily nektar transaction low litigation settlement proceed approximately million primarily merck settlement low outlicense proceed approximately million primarily biogen roche transaction billion change cash flow operating activity compare primarily attributable high cash collection time payment ordinary course business approximately million low income tax payment approximately billion litigation settlement proceed approximately million primarily merck settlement outlicensing proceed million primarily biogen roche transaction partially offset high licensing payment approximately million primarily cytomx halozyme nitto denko transaction high contribution pension plan approximately million investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security original maturity great day time purchase reduce proceed business divestiture include royalty sale maturity marketable security million change cash flow investing activity compare primarily attributable low net sale maturity marketable security maturity great day approximately million high net acquisition payment approximately million primarily purchase million share nektar common stock partially offset high business divestiture proceed approximately million primarily divestiture manufacturing operation sword ireland certain mature brand billion change cash flow investing activity compare primarily attributable low net sale marketable security maturity great day approximately million low business divestiture proceed approximately million primarily certain otc brand investigational hiv medicine business high asset acquisition payment approximately million primarily acquisition ifm financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing million change cash flow financing activity compare primarily attributable low repurchase common stock billion primarily accelerated share repurchase agreement partially offset low net borrowing billion primarily issuance longterm debt repurchase common stock billion change cash flow financing activity compare primarily attributable high repurchase common stock billion primarily accelerated share repurchase agreement partially offset high net borrowing activity million primarily fund repurchase common stock annual report contractual obligation offbalance sheet arrangement payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb deem repatriation transition tax total include estimate future interest payment periodic cash settlement derivative include shortterm uncertain tax benefit uncertainty timing resolution exclude pension liability uncertainty timing resolution addition commit aggregate billion potential future research development milestone payment party inlicense asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer consolidated financial statementsnote alliance information alliance offbalance sheet arrangement material reasonably likely material financial condition result operation sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis bristolmyer squibb maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard refer consolidated financial statementsnote accounting policy recently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize follow fivestep model identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience gtn adjustment follow category gtn adjustment involve significant estimate judgment information obtain external source refer consolidated financial statementsnote revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability annual report rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount cms medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual non country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loe estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model estimate level inventory distribution channel project demand estimate product return present liability use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sell customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information pension benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover lump sum election rate healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citi pension discount curve plan present value benefit obligation december pension plan determine discount rate assume discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately million expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment bristolmyers squibb retirement income plan pension expense determine average expect longterm rate return plan asset plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit refer consolidated financial statementsnote retirement benefit bristolmyers squibb longlive asset intangible asset intangible asset billion december include license million million allocate unapproved product develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loe pricing pressure adverse regulatory change clinical study result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation property plant equipment property plant equipment test impairment current fact circumstance require review include likely asset dispose prior estimate remain useful life additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation impairment relate charge certain manufacturing facility million million million additional charge continue occur result company restructuring action announce asset heldforsale follow criterion consider concluding asset classify heldforsale management commitment plan sell availability immediate sale present condition initiation active program identify buyer probability complete sale year actively market sale reasonable price relation current fair value likelihood significant change plan plan withdraw criterion meet balance sheet date asset liability present separately balance sheet heldforsale low carrying fair value cost sell long depreciate amortize classify heldforsale classify million asset million liability heldforsale december relate plan sale upsa consumer health business division bms manufacture market pain treatment otc product domestic sale france export sale outside france income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life discuss fully consolidated financial statementsnote income taxis provisional tax charge billion attributable onetime deem repatriation transition tax certain foreign earning recognize fourth quarter accounting reduction defer tax asset tax rate complete december tax charge deem repatriation transition tax complete december provisional tax charge deem repatriation transition tax reduce million annual report prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer consolidated financial statementsnote accounting policy recently issue accounting standardsincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer consolidated financial statementsnote accounting policy recently issue accounting standardscontingencie note income taxis note legal proceeding contingency bristolmyer squibb product pipeline development program manage portfolio basis early discovery latestage development include balance early stage latestage program support future growth late stage program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual expense year opdivo investigational compound market product represent great expense year latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product latestage pipeline product indication date development august approval japan treatment adjuvant melanoma approval adjuvant treatment adult patient involvement lymph node july metastatic disease undergo complete resection melanoma announce result phase iii checkmate trial evaluate opdivo versus yervoy patient stage iiibc stage melanoma high risk recurrence follow june complete surgical resection demonstrate statistically long recurrencefree survival opdivo primary endpoint study versus yervoy minimum followup month key subgroup include disease stage braf mutation status announce june fda lift partial clinical hold place checkmate randomize openlabel phase iii study evaluating addition opdivo pomalidomide juneaugust dexamethasone patient relapse refractory multiple myeloma decision multiple myeloma follow consultation fda agreement amendment study protocol august company discontinue enrollment study follow futility analysis approval china treatment locally advanced metastatic nsclc prior june platinumbase chemotherapy adult patient egfr alk genomic tumor aberration nsclc announce pivotal randomize phase iii checkmate trial evaluate opdivo versus docetaxel predominantly chinese population previously treat advanced april nsclc demonstrate superior overall survival benefit primary endpoint regardless pdl expression tumor histology acceptance china sbla filing patient previously treat metastatic january recurrent scchn scchn announce twoyear overall survival datum checkmate phase iii study evaluating opdivo compare investigator choice chemotherapy cetuximab docetaxel opdivo april methotrexate patient recurrent metastatic scchn failure platinumbase therapy announce topline result phase iii checkmate study meet primary october endpoint overall survival opdivo versus chemotherapy patient previously treat relapse sclc sclc fda approval treatment option patient metastatic sclc august cancer progress platinumbase chemotherapy line therapy august approval japan patient mpm progress chemotherapy approval japan week minute infusion dose administration schedule august opdivo indication announce preliminary datum ongoing pivot phase iii study evaluate combination opdivo nektar investigational medicine nktr preliminary result present american society clinical oncology report june safety efficacy biomarker datum patient enrol phase doseescalation stage study patient consecutively enrol select dose expansion cohort phase approval fourweek opdivo dose schedule infuse minute option patient advance melanoma previously treat rcc april approval twoweek opdivo dosing option infuse minute replace weightbase dose approve monotherapy indication fda approval company sbla update opdivo dosing include infuse march week majority approve indication shorter minute infusion approve indication annual report product indication date development announce new datum cohort checkmate study opdivo plus low october dose yervoy demonstrate durable clinical benefit firstline treatment patient msih dmmr mcrc crc fda approval opdivo plus lowdose yervoy treatment adult pediatric patient july year old msih dmmr mcrc progress follow treatment fluoropyrimidine oxaliplatin irinotecan announce result interim analysis phase checkmate trial evaluate opdivoyervoy patient mcrpc show asymptomatic minimally symptomatic patient disease progress secondgeneration hormone therapy mcrpc february receive chemotherapy cohort median followup month objective response rate additionally patient disease progress taxanebase chemotherapy cohort median followup month objective response rate announce fouryear datum phase iii checkmate clinical trial continue october demonstrate durable longterm survival benefit firstline combination opdivo melanoma yervoy versus yervoy patient advance melanoma approval japan opdivoyervoy combination chemotherapynaive patient unresectable melanoma announce followup datum evaluate opdivo monotherapy opdivo combination yervoy patient platinumpretreate muc result phase iii checkmate muc october trial show patient receive combination opdivo mgkg plus yervoy experience high objective response rate compare receive opdivo mgkg plus yervoy mgkg opdivo announce voluntary withdrawal company sbla opdivo plus low dose yervoy treatment firstline advanced nsclc patient tmb great january equal mutation megabase datum checkmate available pdufa goal date announce update regulatory action chmp ongoing opdivoyervoy review application indication metastatic firstline nsclc opdivo plus lowdose yervoy patient tmb great equal mutation megabase october chmp request additional information checkmate include overall nsclc survival analysis opdivoyervoy patient tmb mutation megabase announce result phase iii checkmate trial evaluate opdivo plus lowdose yervoy opdivo plus chemotherapy versus chemotherapy patient june firstline nsclc pdl expression squamous nonsquamous tumor histology extend progressionfree survival announce ema validate type variation application treatment adult patient firstline metastatic nsclc tmb greater equal mutation megabase announce new result phase iii checkmate study show therapy february opdivo plus lowdose yervoy continue demonstrate longterm survival benefit patient previously untreate advanced metastatic rcc announce approval opdivo plus lowdose yervoy previously untreated patient january intermediate poorrisk advanced rcc approval japan opdivo plus lowdose yervoy treatment unresectable august rcc metastatic rcc announce patientreported outcome datum phase iii checkmate trial intermediate poorrisk patient advance rcc treat opdivo plus lowdose june yervoy versus sunitinib twoyear followup period report significant sustained healthrelate quality life improvement fda approval opdivoyervoy combination previously untreated patient april intermediate poorrisk advanced rcc announce patientreported outcome phase iii checkmate study meet november primary endpoint overall survival opdivoyervoy versus placebo maintenance sclc therapy patient extensivestage sclc completion firstline platinumbase chemotherapy announce finding large realworld datum analysis nvaf patient population november eliquis nvaf age old receive direct oral anticoagulant show eliquis associate low rate stroke systemic embolism major bleed rivaroxaban dabigatran bristolmyer squibb product indication date development receive positive chmp opinion polyarticular jia subcutaneous injection orencia jia january pediatric patient year age fda approval empliciti injection intravenous use combination pomalidomide november dexamethasone treatment adult patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor empliciti rrmm announce ema validate company type variation application empliciti combination pomalidomide lowdose dexamethasone treatment adult september patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression therapy announce approval sprycel tablet powder oral suspension february formulation combination chemotherapy treatment pediatric patient newly diagnose philadelphia chromosomepositive fda expand indication sprycel include treatment pediatric patient december sprycel year age old newly diagnose philadelphia chromosomepositive combination chemotherapy expand indication sprycel include treatment child adolescent cml july aged year year chronic phase philadelphia chromosome positive cml include powder oral suspension approval advance unresectable metastatic melanoma pediatric patient year yervoy melanoma january age older announce result phase study bms oral selective tyk inhibitor tyk september psoriasis deliver significant skin clearance patient moderate severe plaque inhibitor psoriasis special note forwardlooke statement include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act amend section exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base historical performance current expectation projection future financial result goal plan objective involve inherent risk assumption uncertainty include internal external factor delay divert change year cause future financial result goal plan objective differ materially express imply statement statement likely relate thing goal plan objective financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product pende acquisition celgene outcome contingency legal proceeding financial result forwardlooke statement guarantee include important factor cautionary statement included recently file particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date additional risk currently deem immaterial presently know cause forwardlooke event discuss occur require federal security law undertake obligation release publicly update revision forwardlooke statement result new information future event change circumstance date annual report quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward contract manage risk primarily arise certain intercompany purchase sale transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million million december december respectively reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive loss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer consolidated financial statementsnote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt use crosscurrency interest rate swap contract designate hedge company net investment japan subsidiary fair value contract marketable debt security analyze yearend determine sensitivity interest rate change sensitivity analysis basis point increase shortterm longterm interest rate december december expect adverse impact earning material estimate increase basis point longterm interest rate december december decrease fair value longterm debt million million respectively credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer consolidated financial statementsnote financial instrument fair value measurement bristolmyer squibb consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative research development income net total expense earning income taxis provision income taxis net earning noncontrolle interest net earning attributable bms earning common share basic diluted consolidated statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive lossincome net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive lossincome comprehensive income comprehensive incomeloss attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement annual report consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm debt obligation account payable accrue liability defer income income taxis payable total current liability defer income income taxis payable pension liability longterm debt total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million common share total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty asset acquisition charge lossgain equity investment adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable security purchase marketable security capital expenditure divestiture proceed acquisition payment net cash inprovide investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement annual report note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function determination single segment consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period information product regional revenue note revenue use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation lossgain equity investment previously present impairment charge adjustment consolidated statement cash flow present separately revenue recognition effective january adopt asc modify retrospective method refer note revenue detailed discussion accounting policy relate revenue recognition include defer revenue royalty refer note alliance detail alliance income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement bristolmyer squibb cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable debt security marketable debt security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity marketable debt security review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition investment equity security investments equity security readily determinable fair value record fair value change fair value record income net investment equity security readily determinable fair value record cost minus impairment plus minus change estimate fair value result observable price change orderly transaction identical similar investment issuer change estimate fair value investment equity security readily determinable fair value record income net investment own company account equity method accounting ability exercise significant influence operate financial decision investee maintain share net income loss equity investment account equity method include income net investment equity security readily determinable fair value investment equity account equity method assess potential impairment quarterly basis base qualitative factor inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition amount allocate lead investigational compound asset acquisition expense date acquisition annual report goodwill acquire inprocess research development intangible asset fair value acquire intangible asset typically determine incomebased approach refer excess earning method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation reduce number facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incurred advertising product promotion cost advertising product promotion cost expense incurred advertising product promotion cost include marketing sell administrative expense million million million foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive lossincome research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner upfront contingent development milestone payment asset acquisition investigational compound include research development expense alternative future use bristolmyer squibb cash flow payment license asset acquisition investigational compound include operating activity outlicense proceed payment acquisition ownership interest legal entity include acquisition meet accounting definition business include investing activity divestiture proceed royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty asset acquisition charge gain loss equity investment gain loss debt redemption recently adopt accounting standard revenue contract customer amend guidance revenue recognition adopt quarter modify retrospective method cumulative effect change recognize retain earning new guidance refer asc require entity recognize revenue expect entitle transfer promise good service customer replace exist revenue recognition standard gaap fivestep model utilize achieve core principle identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied timing recognize revenue typical net product sale customer significantly change transaction price long require fix determinable certain variable consideration recognize prior occurrence resolution contingent event result certain revenue previously defer prior standard transaction price fix determinable account variable consideration recognize early provide term sufficient reliably estimate ultimate price expect realize estimate future royalty contingent fee relate certain arrangement recognize prior party sale event occurring extent probable significant reversal estimate cumulative revenue occur new guidance pertaining separation licensing right relate fee recognition significantly change timing recognize revenue exist alliance arrangement currently generate revenue timing royalty salesbase milestone form contingent consideration result divestiture business royaltie salesbase milestone license arrangement change cumulative effect accounting change result recognize contract asset million million increase retain earning net tax cumulative effect primarily attribute royalty licensing right reacquire alliance partner expect receive future eligible licensing exclusion result new guidance cumulative effect adjustment revenue approximately million low compare report previous guidance refer note revenue information gain loss derecognition nonfinancial asset amend guidance gain loss derecognition nonfinancial asset asc adopt quarter modify retrospective method amendment clarify scope asset derecognition guidance add guidance partial sale nonfinancial asset clarify recognize gain loss transfer nonfinancial asset contract noncustomer certain transaction sale transfer product right constitute business require account similar asc include potential recognition variable consideration amend guidance result early recognition variable consideration depend fact circumstance transaction cumulative effect accounting change result recognize contract asset million million increase retain earning net tax cumulative effect primarily attribute royalty termination fee licensing right reacquire party expect receive future eligible licensing exclusion result new guidance cumulative effect adjustment income net approximately million low compare report previous guidance annual report presentation net periodic pension postretirement benefit amend guidance require net periodic benefit component define benefit pension postretirement plan service cost record outside income operation income adopt quarter retrospective basis cost product sell marketing sell administrative research development expense increase aggregate correspond offset income net adjust amount adoption new guidance follow year end december dollar million report adjust report adjust cost product sell marketing sell administrative research development income net definition business amend guidance revise definition business adopt prospectively quarter amendment provide initial screen substantially fair value gross asset acquire disposed concentrated single identifiable asset group similar identifiable asset integrate set asset activity represent business screen meet set include input substantive process significantly contribute ability create output set represent business amendment narrow definition term output require transfer organize work force output exist amend guidance result transaction account asset future impact result operation dependent individual fact circumstance transaction recognition measurement financial asset liability amend guidance recognition measurement presentation disclosure financial instrument adopt modify retrospective method quarter new guidance require fair value adjustment equity investment readily determinable fair value report earning new guidance require qualitative impairment assessment equity investment readily determinable fair value base observable price change charge earning impairment exist cumulative effect accounting change result million reduction comprehensive lossincome correspond million increase retain earning net tax refer note income net information impact result operation accounting hedging activity amend guidance derivative hedge adopt modify retrospective method quarter amend guidance revise expand item eligible hedge accounting simplifie hedge effectiveness testing change time recognition presentation certain hedge item certain disclosure requirement modify hedging activity prospective basis adoption amend standard material impact company result operation reclassification certain tax effect accumulate comprehensive income amend guidance reclassification certain tax effect accumulate comprehensive income adopt prospectively fourth quarter new guidance permit reclassification income tax effect amount record accumulate comprehensive income impact tax cut job act retain earning company record cumulative effect adjustment increase accumulate comprehensive loss million corresponding increase retain earning collaborative arrangement amend guidance clarify interaction asc revenue contract customer asc collaborative arrangement adopt retrospectively quarter amend guidance clarifie certain transaction collaborative arrangement participant account present revenue asc adoption amend guidance impact company result operation bristolmyer squibb recently issue accounting standard adopt lease february fasb issue amend guidance lease accounting amend guidance require recognition right ofuse asset lease liability initially measure present value future lease payment lease term long month amend guidance adopt january modify retrospective approach company assessment amend guidance substantially complete include implementation leasing software system procure party vendor gather lease information datum assessment reasonable certainty exercise renewal termination option evaluation change enhancement process internal control base assessment intend elect package practical expedient adoption apply shortterm lease recognition exemption lease term month include option purchase underlie asset reasonably certain exercise apply portfolio approach discount real property lease liability company incremental borrowing rate real property lease provide implicit rate lease term vary base nature operation market dynamic country lease facility classify operating lease remain lease term year comprise approximately total lease obligation discount value approximately million december amend guidance expect materially impact company result operation recognition rightofuse asset lease liability sublease income material company result operation cumulative effect accounting change expect material company result operation financial instrument measurement credit loss june fasb issue amend guidance measurement credit loss financial instrument entity require use forwardlooke estimate loss model availableforsale debt security credit loss recognize allowance reduction amortize cost guidance effective january early adoption permit modify retrospective approach amend guidance expect materially impact company result operation goodwill impairment testing january fasb issue amend guidance simplifie recognition measurement goodwill impairment loss eliminate step quantitative impairment test result impairment charge require report unit carry exceed fair value allocate goodwill guidance effective prospective basis january early adoption permit interim annual goodwill impairment test perform january amend guidance expect materially impact company result operation annual report note revenue follow table summarize disaggregation revenue nature year end december dollar million net product sale alliance revenues revenues total revenue net product sale represent company total revenue year end december product sell principally wholesaler distributor less extent directly retailer hospital clinic government agency pharmacie customer order generally fulfil day receipt result minimal order backlog contractual performance obligation usually limit transfer control product customer transfer occur shipment receipt product certain nonus country consider customer obtain legal title product company obtain right payment point customer able direct use obtain substantially remain benefit product gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc wholesaler initially invoice contractual list price payment term typically day base customary practice country exception certain biologic product include opdivo yervoy empliciti day day revenue reduce wholesaler list price time recognition expect chargeback discount rebate sale allowance product return refer gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program medicare medicaid drug pricing program contain pricing implication mandatory discount pricing protection wholesaler list price discount medicare beneficiarie coverage gap addition nonus government program include different pricing scheme cost cap volume discount outcomebase pricing pricing clawback determine sale individual company aggregation company participate specific market chargeback cash discount reflect reduction receivables settle issuance credit customer typically month rebate discount adjustment include medicaid medicare reflect liability settle cash payment customer typically time period range month year significant judgment require estimate gtn adjustment consider legal interpretation applicable law regulation historical experience payer channel mix current contract price applicable program unbilled claim processing time lag inventory level distribution channel follow table summarize gtn adjustment year end december dollar millions gross product sale gtn adjustmentsa chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale include adjustment provision product sale prior period result change estimate million million million year end december respectively bristolmyer squibb alliance revenue consist primarily amount relate collaboration outlicense arrangement arrangement evaluate represent contract scope revenue recognition guidance entirety contain aspect scope guidance directly reference base application guidance relate derecognition nonfinancial asset asc performance obligation identify separate party benefit directly right good service readily available resource right good service highly interdependent interrelate transaction price arrangement include fix upfront amount variable consideration contingent development regulatory milestone salesbase milestone royalty likely method estimate contingent development regulatory salesbase milestone ultimate outcome binary nature expect value method estimate royalty broad range potential outcome exist instance royalty relate license variable consideration include transaction price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve significant judgment require estimating variable consideration recognize assess factor outside bmss influence likelihood regulatory success limited availability party information expect duration time resolution lack relevant past experience historical practice offering fee concession large number broad range possible amount extent arrangement include multiple performance obligation separable transaction price assign distinct performance obligation reflective relative standalone selling price recognize point time transfer control type outlicense arrangement typically utilize arrangement outlicense intellectual property party performance obligation arrangement include license additional performance obligation supply product request party collaboration arrangement include transfer license party jointly develop commercialize product outlicense arrangement consist single performance obligation satisfy execution agreement development commercialization right transfer party upfront fee recognize immediately include income net contingent development regulatory milestone amount assess period likelihood achievement typically constrain recognize uncertainty subsequently resolve milestone include income net salesbase milestone royalty recognize milestone achieve subsequent sale occur salesbased milestone include income net royalty include alliance revenue certain outlicensing arrangement include contingent performance obligation supply commercial product party request license supply obligation account separate performance obligation consider distinct party benefit license supply resource readily available obligation separately identifiable obligation contract accordance revenue recognition guidance consider standalone selling price situation upfront fee contingent development regulatory milestone amount salesbase milestone royalty allocate license recognize manner describe consideration supply obligation usually base stipulate costplus margin contractual term represent standalone selling price supply consideration recognize point time transfer control product party include alliance revenue fee allocation license supply represent consideration company expect entitle satisfaction separate performance obligation collaboration arrangement unique nature party active participant operating activity expose significant risk reward depend commercial success activity performance obligation inherent arrangement include transfer certain development commercialization right ongoing development commercialization service product supply obligation certain product supply obligation consider distinct account separate performance obligation similar manner discuss performance obligation consider distinct combine single performance obligation transfer right highly integrate interrelated obligation jointly develop commercialize product party result upfront fee recognize ratably time expect period collaboration activity include income net license combine development commercialization obligation contingent development regulatory milestone long constrain recognize similar manner prospective basis royalty profit sharing recognize underlie sale profit occur include alliance revenue refer note alliance information annual report follow table summarize disaggregation revenue product region year end december dollar millions prioritize brand opdivo eliquis orencia sprycel yervoy empliciti establish brand baraclude reyataz franchise sustiva franchise hepatitis franchise brand total revenues united states europe rest world othera total revenue revenue include royalty alliancerelate revenue product sell regional commercial organization follow table summarize contract asset december january dollar millions december january prepay expense asset total contract asset contract asset primarily estimate future royalty termination fee eligible licensing exclusion recognize adoption asc asc contract asset reduce receivable increase period underlie sale occur contingent development regulatory milestone outlicense arrangement billion constrain recognize consider likelihood significant reversal cumulative revenue occur cumulative catchup adjustment revenue affect contract asset contract liability material year end december revenue recognize performance obligation satisfy prior period million year end december consist primarily royalty outlicense arrangement revise estimate gtn adjustment relate prior period sale sale commission incremental cost obtain customer contract expense incur amortization period year note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region refer collaboration alliance partner alliance partner bristolmyers squibb common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenues sale commercial product consider bms ongoing major central operation refer note revenue information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenues sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms development copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present income net activity perform time relate sale commercial product include bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include income net earn payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize certain prior period amount include revise exclude amount arrangement long meet criterion collaboration arrangement year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development income net select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone payment annual report specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms salesbased fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms pfizer manufacture product alliance bms principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale price endcustomer record transfer control product pfizer company allocate consideration right transfer pfizer right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize expect period bms copromotion obligation market exclusivity period bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include income net eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing income net amortization defer income select alliance balance sheet information december dollar million receivables account payable deferred income bristolmyer squibb otsuka bms otsuka copromote sprycel party actively participate governance committee bms control decision make bms responsible development manufacture product principal end customer product sale fee pay otsuka base net sale level oncology territory japan equate million billion annual net sale plus net sale excess billion summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale oncology territory payment otsuka cost product sell oncology fee bms worldwide commercialization agreement otsuka codevelop copromote abilify portion agreement expire april portion expire june country bms exclusive right sell abilify expiration occur countrybycountry basis expiration canada january ono bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer ono grant bms exclusive license development commercialization ono onos prostaglandin receptor antagonist bms acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right bms pay million ono include research development expense ono eligible receive subsequent clinical regulatory salesbase milestone payment million royalty country bms exclusive licensing right bms provide ono right accept nktr alliance completion phase clinical study opdivo nktr ono territory right exercise ono partially reimburse bms development cost incur study share certain future development cost contingent milestone payment profit loss collaboration nektar summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment annual report gilead bms gilead operate joint venture europe develop commercialize combination product name atripla combine bms sustiva gilead truvada joint venture consolidate gilead principal end customer product sale bms receive percentage end customer sale record alliance revenue joint venture continue party terminate arrangement patent expire allow market exclusivity atripla prior bms gilead operate joint venture canada atripla terminate follow launch generic version sustiva thirdparty result deferred income alliance receivables attribute sustiva product hold joint venture december reduce million reflect posttermination sell price bms entitle fee equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price fee reduce atripla net sale multiply ratio describe bms supply sustiva cost plus markup gilead threeyear period terminate supply agreement notice period summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate nektar bms nektar commence worldwide license collaboration development commercialization nktr nektar investigational immunostimulatory therapy design selectively expand specific cancerfighting cell natural killer cell directly tumor microenvironment opdivo nktr combination therapy currently phase clinical study multiple cancer indication phase iii clinical study melanoma rcc joint development plan agree party contemplate development indication tumor type party responsible supply product bms share development cost associate therapy comprise bms medicine combination nktr subject certain cost cap nektar party jointly commercialize therapy subject regulatory approval bms share global nktr profit loss subject certain annual loss cap nektar bm pay nektar billion right discuss million share nektar common stock represent ownership interest bms equity ownership subject certain lockup standstill voting provision fiveyear period upfront payment allocate equity investment million consider nektar stock price date close current limitation trading security remain billion upfront payment allocate right discuss include research development expense second quarter bms pay billion achievement contingent development regulatory salesbase milestone life alliance period research development expense payable agreement nektar million year end december bristolmyers squibb abbvie bms abbvie jointly develop commercialize empliciti humanize monoclonal antibody treatment multiple myeloma party participate development commercialization committee bms final decision make authority abbvie fund global development cost bms solely responsible supply distribution sale marketing activity principal end customer product sale abbvie share profit loss pay tiere royalty outside abbvie entitle receive additional million certain regulatory event occur million certain sale threshold achieve agreement terminate immediately bm party material breach subsequent notice period summarize financial information relate alliance follow year end december dollar millions revenues abbvie alliance net product sale payment abbvie cost product sell profit sharing note acquisition divestiture license arrangement acquisition acquisition evaluate determine business asset group asset follow transaction account asset acquisition determined business term define asc primarily significant process acquire result amount allocate lead investigational compound expense capitalize consideration transaction execution year allocate follow defer tax contingent dollar million year upfront payment expense assetsa consideration ifmb cormorant padlock relate net operating loss tax credit carryforward include million certain negotiation right collaborate license acquire nlrp antagonist program newly form entity establish shareholder ifm ifm bms acquire outstanding share ifm private biotechnology company focus develop therapy modulate novel target innate immune system treat cancer autoimmunity inflammatory disease acquisition provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer contingent consideration include development regulatory salesbase milestone payment million include research development expense follow commencement phase clinical study bms pay million additional contingent milestone subsequent product select ifm preclinical sting nlrp agonist program include contingent consideration table cormorant bms acquire outstanding share cormorant private pharmaceutical company focus develop therapy cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary mechanism action tcell direct antibodie costimulatory molecule contingent consideration include development regulatory milestone payment million include research development expense conclusion month reversion option period annual report padlock bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patients padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease contingent consideration include development regulatory milestone payment cardioxyl bms acquire outstanding share cardioxyl private biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase development acute decompensate heart failure contingent consideration include development regulatory salesbase milestone payment million include research development expense follow commencement phase clinical study flexus bms acquire outstanding share flexus private biotechnology company focus discovery development novel anticancer therapeutic acquisition provide bms right preclinical small molecule idoinhibitor target immunotherapy addition bms acquire flexus idotdo discovery program include idoselective idotdo dual tdoselective compound contingent consideration include development regulatory milestone payment million million include research development expense respectively follow commencement phase phase phase iii clinical study divestiture follow table summarize proceed gain royalty income result divestiture revenue pretax earning relate divestiture asset heldforsale material period present exclude divestiture gain proceedsa divestiture gain royalty income dollar millions diabete business erbitux business manufacturing operation plavix avaproavalide investigational hiv business otc business mature brand include royalty receive subsequent relate sale asset business diabete business february bms astrazeneca terminate diabetes business alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan purchase bmss manufacturing facility locate mount vernon indiana consideration transaction include billion payment closing contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable tiere royalty payment range base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee bristolmyer squibb consideration allocate development supply agreement amortize applicable service period amortization defer income attribute development agreement end december million include income net sale service consider bmss ongoing major central operation amortization defer income attribute supply agreement end december record alliance revenues revenues attribute supply agreement include alliance revenues material royalty present income net million million million contingent consideration million receive result additional gain achievement regulatory approval milestone september bms transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib royalty present income net million million million november bm transfer percentage future royalty right portion onglyza farxiga net product sale royalty pharma transfer right represent approximately potential future royalty bms entitle product exchange transfer bms receive additional tieredbase royalty onglyza farxiga net product sale royalty pharma royalty present income net million erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly october bms transfer right erbitux north america lilly exchange tiere salesbase royalty september include income net royalty earn million million million bm transfer cocommercialization right japan merck kgaa exchange salesbase royalty include income net earn royalty earn million million result adoption asc quarter estimate future royalty result transfer right merck kgaa record cumulative effect adjustment retain earning subsequent change estimate record income net refer note accounting policy recently issue accounting standard detail manufacturing operation bms sell small molecule active pharmaceutical ingredient manufacturing operation sword ireland biotek approximately million subject certain adjustment initial proceed million receive quarter transaction account sale business divestiture include transfer facility majority employee site inventory certain thirdparty contract manufacturing obligation asset reduce estimate relative fair value consider purchase price result impairment charge million include cost product sell biotek provide certain manufacturing service bms plavix avaproavalide sanofi reacquire bms codevelopment cocommercialization agreement plavix avaproavalide consideration transfer right include quarterly royalty december million terminal payment receive million allocate optout market million allocate bms interest europe asia territory partnership royalty expect receive portion terminal payment allocate optout market reflect contract asset cumulative effect adjustment adoption asc bm fulfil performance obligation million allocate bms partnership interest defer december recognize income net transfer sanofi refer note accounting policy recently issue accounting standard detail royalty earn sanofi territory cover americas australia optout market present alliance revenue aggregate million million million royalty attribute territory cover europe asia earn territory partnership pay bms include equity net income affiliate amount million million million annual report investigational hiv business bm sell investigational hiv medicine business consist number program different stage discovery development viiv healthcare bm receive million entitle receive viiv healthcare contingent development regulatory milestone payment billion salesbase milestone payment billion future tiere royalty bms earn transitional fee million million certain service respectively otc business bm sell reckitt otc business contain brand sell primarily mexico brazil million gain million include trademark inventory certain asset exclusively relate product manufacturing facility locate mexico primarily dedicated product mature brand divestiture include brand sell cheplapharm result proceed million divestiture gain million asset heldforsale bms agree sell upsa consumer health business billion transaction expect close second quarter account sale business business account heldforsale december accordingly asset million reclassify asset heldforsale include prepaid expense include million receivable million inventory million property plant equipment million goodwill additionally liabilitie million reclassify liability relate asset heldforsale include accrue liability include million accrue liability million account payable million defer tax liability million liability december bms agree sell facility wallingford connecticut transaction close account sale asset facility account heldforsale december reduce estimate relative fair value result impairment charge million include research development expense licensing arrangement promedior bms purchase warrant give bms exclusive right acquire promedior biotechnology company lead asset prm develop treatment ipf warrant exercisable delivery phase datum follow ipf phase clinical study direct promedior upfront payment allocate warrant million include research development expense remain million million upfront payment allocate promedior obligation complete phase study amortize expect period phase study allocation determine level input bms notify promedior exercise warrant purchase outstanding share promedior halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms medicine halozyme enhanze drugdelivery technology technology allow rapid delivery large volume injectable medication subcutaneous delivery bms pay million halozyme access technology include research development expense bms designate multiple target include develop enhanze technology option select additional target year effective date maximum target bms pay contingent development regulatory salesbase milestone million achieve nominate collaboration target additional milestone payment combination product future royalty sale product enhanze technology bristolmyer squibb cytomx bms expand strategic collaboration cytomx discover novel therapy cytomxs proprietary probody platform original collaboration discover develop commercialize probody therapeutic bms select oncology target include ctla pursuant expand agreement cytomx grant bms exclusive worldwide right develop commercialize probody therapeutic additional target bms pay cytomx million right initial target expense prior bms pay million cytomx access additional target include research development expense bms reimburse cytomx certain research cost collaboration period pay contingent development regulatory salesbase milestone million achieve collaboration target future royalty biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy biogen pay million bms include income net bms entitle contingent development regulatory salesbase milestone payment million achieve future royalty bms originally acquire right compound acquisition ipierian biogen assume bmss remain obligation stockholder ipierian roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche pay million bms include income net bms entitle contingent development regulatory milestone payment million achieve future royalty nitto denko bms nitto denko enter exclusive worldwide license agreement grant bms right develop commercialize nitto denko investigational sirna molecule target hsp vitamin contain formulation include nitto denko lead asset ndls currently phase study treatment advance liver fibrosis bms pay million nitto denko include research development expense bms pay contingent development regulatory sale base milestone million achieve future royalty agreement grant bms option receive exclusive license hsp sirnas vitamin contain formulation treatment lung fibrosis organ fibrosis fstar bms acquire exclusive option purchase fstar lead asset antiher antibody fragment development treatment breast gastric cancer welldefine population herpositive patient bms discontinue development exercise option result iprd charge million include research development expense attribute noncontrolle interest annual report note income net year end december dollar million interest expense investment income lossgain equity investment provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investment include fair value adjustment million relate company equity investment nektar litigation settlement include million bms share patentinfringement settlement relate merck antibody keytruda royalty licensing income include royalty result business divestiture intellectual property legal settlement upfront licensing fee include million biogen roche transition service fee primarily relate divestiture diabete investigational hiv medicine business note restructure october company announce restructure plan evolve streamline operating model expect incur charge connection employee workforce reduction early site exit majority charge expect incur range billion billion consist employee termination benefit cost contract termination cost accelerate depreciation impairment charge site exit cost cash outlay connection action expect approximately total charge charge approximately billion recognize action announcement include impairment charge small molecule manufacturing operation sword ireland restructuring charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market restructure charge addition action recognize prior primarily relate specialty care transformation initiative design create simplify organization function geographic market addition accelerate depreciation charge incur connection expect early exit small molecule manufacturing site cruiserath ireland facility wallingford connecticut refer note acquisition divestiture license arrangement information employee workforce reduction approximately bristolmyer squibb follow table summarize charge activity relate restructuring action year end december dollar million employee termination cost termination cost provision restructuring accelerate depreciation asset impairment shutdown cost total charge year end december dollar million cost product sell marketing sell administrative research development income net total charge year end december dollar million liability january charge change estimate provision restructure foreign currency translation payment liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision annual report effective tax rate reconciliation effective tax rate statutory federal income tax rate earning income taxis dollar million earning income taxis nonus total statutory rate deem repatriation transition tax defer tax remeasurement global intangible low tax income gilti foreign tax effect certain operation ireland puerto rico switzerland federal valuation allowance federal state foreign contingent tax matter federal research base credit goodwill allocate divestiture brand prescription drug fee nondeductible charge puerto rico excise tax domestic manufacturing deduction state local taxis net valuation allowance foreign new tax reform legislation enact december know tax cut job act act act move worldwide tax system quasiterritorial tax system comprise broad complex change tax code include limited reduce tax rate add deem repatriation transition tax certain foreign earning profit generally eliminate federal income taxis dividend foreign subsidiary include certain income control foreign company taxable income gilti create new minimum tax refer base erosion antiabuse income tax limit certain federal research base credit eliminate domestic manufacturing deduction aspect act effective additional tax expense billion recognize fourth quarter enactment include billion onetime deem repatriation transition tax previously untaxe post foreign earning profit include related tax reserve earning effectively tax rate extent specify foreign corporation hold cash certain asset rate remain earning profit remain additional tax expense include adjustment measure net defer tax asset new tax rate provisional tax charge deem repatriation transition tax include related tax reserve staff accounting bulletin reduce million accounting reduction defer tax asset tax rate complete december tax charge deem repatriation transition tax complete december prior enactment act earning certain manufacturing operation low tax jurisdiction switzerland ireland puerto rico indefinitely reinveste result transition tax act company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply company remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable bms operate favorable tax grant puerto rico schedule expire prior valuation allowance set result nektar equity investment fair value loss consider limited capital loss federal state foreign contingent tax matter include million tax benefit respect lapse statute bristolmyers squibb goodwill allocate business divestiture brand prescription drug fee deductible tax purpose charge primarily acquisition relate milestone payment shareholder deductible tax purpose include cormorant ifm flexus cardioxyl ifm flexus padlock cormorant puerto rico impose excise tax gross company purchase price good sell manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize provision income taxis excise tax incur defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee pension postretirement benefit intercompany profit inventory item foreign defer tax asset sharebase compensation total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax asset net recognize deferred income taxis noncurrent income taxis payable noncurrent liability relate asset heldforsale total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance billion establish follow item billion primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal defer tax asset include equity fair value adjustment federal net operating loss carryforward annual report change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition non rate change balance end year income tax payment million million billion business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense reasonably possible new issue raise tax authority require adjustment unrecognized tax benefit estimate adjustment reasonably time reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction bristolmyer squibb follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share basic earning share dilute note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective nav underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial asset liability december annual report financial asset liability measure fair value recur basis summarize december december dollar million level level level level cash cash equivalent money market security marketable security certificate deposit commercial paper corporate debt security equity investment derivative asset equity investment derivative liability availableforsale security change fair value equity investment include income net adoption asu quarter follow table summarize debt equity security classify availableforsale december december gross unrealize gross unrealized amortize amortize dollar million cost gain loss fair value cost gain loss fair value certificate deposit commercial paper corporate debt security equity investmentsa equity investmentsb total december december dollars million current marketable security noncurrent marketable securitiesc assetsa total include equity investment readily determinable fair value measure fair value option december include equity fix income fund measure fair value option december refer note accounting policy recently issue accounting standard information noncurrent marketable security mature year december december equity investment measure fair value exclude table limit partnership equity method investment million december million december equity investment readily determinable fair value million december million december amount include asset adjustment equity investment readily determinable fair value million result observable price change similar security issuer record income net follow table summarize net loss record equity investment readily determinable fair value hold december year end dollar million december net loss recognize net gain recognize equity investment sell net unrealized loss equity investment hold bristolmyer squibb qualifying hedge nonqualifye derivative cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase sale transaction certain foreign currency transaction fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning adoption amend guidance derivative hedge entire change fair value hedge instrument include assessment hedge effectiveness record derivative qualify cash flow hedge component comprehensive lossincome net gain loss foreign currency forward contract expect reclassify net earning primarily include cost product sell month notional outstanding foreign currency forward contract primarily attribute euro billion japanese yen million december earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis foreign currency forward contract designate hedge instrument offset exposure certain foreign currency denominate asset liability earning change fair value derivative recognize earning occur net investment hedge nonus dollar borrowing million billion december designate hedge euro currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain remeasurement euro debt million million respectively loss million record foreign currency translation component accumulate comprehensive loss relate offset longterm debt january bm enter million crosscurrency interest rate swap contract mature december designate hedge japanese yen currency exposure company net investment japan subsidiary contract fair value change record foreign currency translation component comprehensive lossincome relate offset pension liability fair value hedge fix float interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range gain loss result change fair value underlie debt attributable hedge benchmark interest rate risk record interest expense associate offset carry value debt specific term notional swap intend match debt hedge change fair value swap record interest expense associate offset derivative asset liability consolidate balance sheet result net impact earning underlie swap terminate prior maturity fair value adjustment underlie debt amortize reduction interest expense remain term debt follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value derivative designate hedge instrument interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract derivative designate hedge instrument foreign currency forward contract include prepay expense asset include accrue liability pension liability annual report follow table summarize financial statement classification gainloss recognize hedging instrument year end december cost cost cost dollar million product sell income net product sell income net product sell income net interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract follow table summarize effect derivative nonderivative instrument designate hedge instrument comprehensive lossincome year end december dollar million derivative qualify cash flow hedge foreign currency forward contract gainloss recognize comprehensive lossincomea reclassify cost product sell reclassify income net derivative qualify net investment hedge crosscurrency interest rate swap contract loss recognize comprehensive lossincome nonderivative qualify net investment hedge non dollar borrowing gainloss recognize comprehensive lossincome expect reclassify earning month debt obligation shortterm debt obligation include december dollar millions commercial paper nonus shortterm borrowing current portion longterm debt total average commercial paper outstanding million million weightedaverage interest rate respectively maximum commercial paper outstanding million outstanding borrowing december maximum commercial paper outstanding billion million outstanding borrowing december bristolmyers squibb longterm debt current portion longterm debt include december dollar million principal value note note note note note euro note note note euro note note note note note note mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost total current portion longterm debt longterm debt fair value longterm debt billion billion december respectively value level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument senior unsecured note issue register public offering notes rank equally right payment bms exist future senior unsecured indebtedness redeemable time predetermine redemption price follow table summarize issuance longterm debt obligation dollar million principal value note note total proceed net discount defer loan issuance cost forward start interest rate swap contract terminate notional realize gain unrealized loss annual report bms repay million note maturity company repurchase certain longterm debt obligation interest rate range follow summarize debt redemption activity dollar million principal carry value debt redemption price loss debt redemptiona include acceleration debt issuance cost gain previously terminate interest rate swap contract relate fee interest payment million million million net amount receive interest rate swap contract december company separate revolve credit facility total billion syndicate lender include billion facility expire september july extendable annually year anniversary date consent lender january exist day billion facility expiring march replace new day billion facility expire january new threeyear billion facility expire january enter credit facility provide customary term condition financial covenant borrowing outstanding revolve credit facility december available financial guarantee provide form bank overdraft facility standby letter credit performance bond approximately billion december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action note receivable december dollar million trade receivable chargeback cash discount bad debt allowance net trade receivables alliance receivables prepay refundable income taxis royaltie vat receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization balance end year bristolmyer squibb note inventory december dollar million finished good work process raw packaging material inventory inventory asset asset include inventory expect remain hand year period note property plant equipment lease december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment united states europe rest world total depreciation expense million million million annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense approximately million million million sublease income capital lease obligation material period present note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year iprd gross intangible asset accumulate amortization total intangible asset annual report period adjustment include year end december reduce goodwill increase accumulate comprehensive loss million attribute goodwill prior acquisition foreign entity previously record correct local currency adjustment impact consolidate result operation material previously report balance sheet amortization expense intangible asset million million million future annual amortization expense intangible asset expect approximately million million million million million intangible asset impairment charge million million million million impairment charge record income net outlicensed asset obtain acquisition zymogenetics inc meet primary endpoint phase clinical study million iprd charge recognize attribute noncontrolle interest bms decline exercise option purchase fstar note accrue liability december dollar million rebate return employee compensation benefit research development dividend royalty brand prescription drug fee liability relate asset heldforsale litigation settlement restructure pension postretirement benefit accrue liabilities bristolmyers squibb note equity common stock capital accumulate treasury stock excess par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january net earnings comprehensive lossincome cash dividend declaredc stock repurchase program stock compensation distribution balance december accounting change cumulative effecta adjust balance january net earnings comprehensive lossincome cash dividend declaredc stock repurchase program stock compensation variable interest entity distribution balance december accounting change cumulative effectb adjusted balance january net earnings comprehensive lossincome cash dividend declaredc stock repurchase program stock compensation adoption asu distribution balance december cumulative effect result adoption asu refer note accounting policy recently issue accounting standard additional information cash dividend declare common share respectively bms stock repurchase program authorize board director allow repurchase open market private transaction include plan establish accordance rule securities exchange act stock repurchase program expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method bms repurchase billion common stock accelerate share repurchase agreement agreement fund combination debt cash annual report component comprehensive lossincome follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge unrealize gainslosse reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial lossesgain amortizationb settlementsb pension postretirement benefit availableforsale security unrealize lossesgain realize gainslossesb availableforsale security foreign currency translation total comprehensive lossincome include cost product sell include income net accumulate balance relate component comprehensive lossincome net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note retirement benefit bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan plan cover employee represent approximately consolidated pension plan asset obligation future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation december plan asset consist primarily fixedincome security december bm announce plan fully terminate bristolmyer squibb retirement income plan plan pension obligation relate plan billion distribute combination lump sum payment eligible plan participant elect payment purchase group annuity contract athene annuity life company athene whollyowne insurance subsidiary athene holding ltd benefit obligation plan december determine plan termination basis assume portion eligible active defer vested participant elect lump sum payment remain obligation expect transfer athene include annuity purchase price premium plan sufficient asset satisfy transaction obligation transaction expect close quarter time company expect record total noncash pretax pension settlement charge approximately billion billion bristolmyer squibb net periodic benefit costcredit define benefit pension plan include dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss settlement curtailment special termination benefit net periodic benefit costcredit pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow dollar million benefit obligation begin year service costbenefit earn year interest cost settlement curtailment actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize asset accrue liability pension liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively annual report additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation december follow discount rate rate compensation increase weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit costcredit year end december follow discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citi pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value approximate fair value plan asset december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset actuarial gain relate plan benefit obligation primarily result increase discount rate actuarial loss relate plan benefit obligation primarily result decrease discount rate gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan result adopt asu refer note accounting policy recently issue accounting standard detail periodic benefit cost credit include income net service cost component include cost product sell research development marketing sell administrative expense bristolmyers squibb postretirement benefit plan comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome securities postretirement benefit plan obligation million million december respectively fair value plan asset million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security shortterm investment fund insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient equity fund venture capital limited partnership total plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund shortterm investment fund classify level fair value hierarchy value nav share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company venture capital limited partnership investment typically redeemable distribution liquidation underlie asset significant unfunded commitment investment essentially liquidation expect occur end remain investment practical expedient redeemable weekly monthly basis annual report investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense target allocation longduration fix income private equity adopt maintain principal define benefit pension plan bristolmyers squibb retirement income plan bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect material estimate annual future benefit payment nonterminate plan include lump sum payment approximately million year subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy obligation plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right restrict stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment number share issue performance share unit vest determine base achievement performance goal base company threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million restrict stock unit market share unit performance share unit total stockbase compensation expense income tax benefit bristolmyers squibb stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value award vest restricted stock unit market share unit performance share unit total intrinsic value stock option exercise fair value restrict stock unit market share unit performance share unit approximate close trading price bms common stock grant date adjust unit eligible accrue dividend addition fair value market share unit performance share unit consider probability satisfy payout factor total shareholder return respectively follow table summarize significant outstanding exercisable option december number weightedaverage weightedaverage aggregate outstanding exercisable remain contractual exercise price intrinsic value million life year share million option outstanding exercisable aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december annual report note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex company apotex settle apotex case case dismiss australian government intervene matter seek maximum damage million aud million plus interest split company sanofi allege loss experience pay high price brand plavix period injunction place company sanofi dispute australian government entitle damage australian government claim pende trial conclude september company expect decision sprycel europe apotex actavis group ptc ehf generics limited mylan unnamed company file opposition epo seek revocation european patent patent cover dasatinib active ingredient sprycel january opposition division epo revoke patent company appeal epos decision epo board appeal february epo board appeal uphold opposition division decision revoke patent orphan drug exclusivity datum exclusivity sprycel expire november epo board appeal decision affect validity sprycel patent outside europe include different patent cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epos opposition division revoke october december epos opposition division uphold validity patent direct use dasatinib treat cml expire company intend appropriate legal action protect sprycel generic approve certain market experience decline european revenue event generic dasatinib product enter market bristolmyers squibb antipd antibody patent opposition litigation september danafarber cancer institute danafarber file complaint massachusetts federal court seek correct inventorship relate patent direct method treat cancer pdl antibodie specifically danafarber seeking add scientist inventor patent october pfizer allow intervene case allege scientist identify danafarber employ company eventually acquire pfizer relevant period february company settle lawsuit pfizer bench trial lawsuit danafarber begin february decision expect eliquis patent litigation twentyfive generic company send company paragraphiv certification letter inform company file anda seek approval generic version eliquis result eliquis patent list fda orange book challenge composition matter patent claim apixaban specifically formulation patent april company partner pfizer initiate patent lawsuit hatchwaxman act generic filer federal district court delaware west virginia august patent trademark office grant patent term restoration composition matter patent restore term eliquis composition matter patent company basis project loe february november company settle lawsuit number anda filer december settlement affect company project loe eliquis pricing sale promotional practice litigation plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix product liability litigation company party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit company face unfiled claim involve product byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf approximately active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp november ninth circuit reverse mdl summary judgment order remand case mdl november california court appeal reverse state court dismissal state court case remand jccp proceeding amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca abilify company otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose district court northern district florida february company otsuka enter master settlement agreement establish propose settlement program resolve abilify compulsivity claim file january mdl state court include california new jersey eliquis company pfizer codefendant product liability litigation relate eliquis plaintiff assert claim include claim wrongful death result bleed allege cause use eliquis january claim remain pende mdl district court southern district new york case remain pende state court remain pende canada case dismiss prejudice mdl claim plaintiff appeal second circuit court appeal company expect decision annual report onglyza company astrazeneca codefendant product liability litigation relate onglyza plaintiff assert claim include claim wrongful death result heart failure cardiovascular injury allege cause use onglyza january claim pende state federal court behalf approximately individual allege ingest product suffer injury significant majority claim pende federal court february judicial panel multidistrict litigation order federal case transfer mdl district court eastern district kentucky company global diabete business divestiture company sell onglyza astrazeneca february potential liability respect onglyza expect share astrazeneca shareholder derivative litigation december shareholder derivative lawsuit file new york state court certain officer director company plaintiff allege thing breach fiduciary duty surround company previously disclose october civil settlement sec allege fcpa violation china company agree payment approximately million disgorgement penalty interest october lawsuit dismiss company receive notice appeal dismiss lawsuit oral argument appeal dismissal schedule february security litigation february separate putative class action complaint file district northern district california district court southern district new york company company chief executive officer giovanni caforio company chief financial officer charle bancroft certain current executive company case california voluntarily dismiss remain complaint allege violation security law company disclosure relate checkmate clinical trial lung cancer fully brief motion dismiss pende court company intend defend vigorously litigation litigation acquisition celgene litigation february complaint file celgene shareholder district court district delaware district court district new jersey district court southern district new york court chancery state delaware seek enjoin company propose acquisition celgene complaint action defendant celgene member celgene board director complaint company burgundy merger sub inc whollyowne subsidiary company form solely purpose complete pende acquisition celgene merge celgene completion acquisition defendant complaint name company defendant style putative class action plaintiff allege violation federal security law breach fiduciary duty connection acquisition celgene company separately tenth complaint style putative class action file court chancery state delaware behalf company shareholder naming member company board director defendant complaint allege member company board director breach fiduciary duty company shareholder fail disclose material information pende acquisition company burgundy merger sub celgene intend defend vigorously lawsuit acquisition flexus litigation february company acquire flexus include right ido inhibitor september incyte corporation incyte sue flexus flexus founder flexus defendant superior court state delaware initial subsequent amend complaint incyte allege claim flexus defendant misappropriation trade secret relate research development incyte ido inhibitor november follow ahalf week trial trade secret jury superior court delaware return defense verdict behalf flexus defendant incyte appeal decision average wholesale price litigation company defendant qui tam whistleblower lawsuit district court eastern district pennsylvania government decline intervene complaint allege company inaccurately report average manufacturer price center medicare medicaid services lower owe similar claim file company court deny company motion dismiss november bristolmyers squibb government investigation like pharmaceutical company company certain subsidiary subject extensive regulation national state local government agency country bms operate result company time time subject governmental inquiry investigation possible criminal charge substantial fine andor civil penalty result government investigation environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site note subsequent event january bms announce company enter definitive merger agreement bms acquire celgene term agreement merger complete celgene shareholder receive share bms common stock cash share celgene common stock hold celgene shareholder receive tradeable contingent value right share celgene represent right receive cash subject achievement future regulatory milestone base closing price share bms common stock january recent trading day prior date announcement merger consideration represent approximately billion consideration receive celgene stockholder fluctuate change price share bms common stock bms expect fund transaction combination exist cash new debt bms expect enter accelerate share repurchase program approximately billion subject closing transaction market condition board director approval company expect transaction close end quarter subject approval bristolmyers squibb celgene shareholder satisfaction customary closing condition regulatory approval annual report note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earningsloss share basica earningsloss share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset longterm debt include current portion bristolmyer squibb follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrative license asset acquisition charge site exit cost research development lossgain equity investment provision restructure litigation settlement divestiture gain royalty license income pension postretirement intangible asset impairment income net increasedecrease pretax income income taxis item income taxis attribute tax reform income taxis increasedecrease net earning second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrative license asset acquisition charge iprd impairment site exit cost research development provision restructure litigation settlement divestiture gain royalty license income pension postretirement loss debt redemption income net increasedecrease pretax income income taxis item income taxis attribute tax reform income taxis increasedecrease net earning noncontrolle interest increasedecrease net earning attributable bms specify item cost product sell accelerate depreciation asset impairment shutdown cost annual report report management management responsibility financial statement management responsible preparation integrity financial information present annual report accompany consolidated financial statement prepare conformity united states generally accept accounting principle apply certain estimate judgment require management opinion consolidated financial statement present fairly company financial position result operation cash flow audit committee board director meet regularly internal auditor deloitte touche llp company independent register accounting firm management review account internal control structure financial reporting matter internal auditor free access audit committee set forth company standard business conduct ethic company firmly commit adhere high standard moral ethical behavior business activity management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include giovanni caforio chief executive officer charle bancroft chief financial officer february bristolmyers squibb control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure define exchange act rule end period cover base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting define exchange act rule supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting information february company amendment registration statement form company pende acquisition celgene company disclose starboard value send notice nomination director company board director company inform starboard value review connection delivery notice starboard value request meet company management pende discussion notice meeting keep confidential company management subsequently meet starboard value multiple occasion vote potential change company board director come annual meeting shareholder date set time file company shareholder expect vote propose acquisition celgene april annual report report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion parsippany new jersey february serve company auditor bristolmyers squibb report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion consolidated financial statement basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate parsippany new jersey february annual report performance graph follow graph compare cumulative total stockholder return common share cumulative total stockholder return company list standard poor index composite peer group major pharmaceutical company comprise abbvie amgen astrazeneca biogen celgene gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assume investment december common share index stock peer group company include reinvestment dividend year end december stock price performance follow graph necessarily indicative future stock price performance bristolmyer squibb peer group bristolmyers squibb year financial summary amount million share datum income statement datum total revenue net earning net earningsloss attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesa total asset longterm debta equity include current noncurrent portion annual report summary abbreviate term bristolmyer squibb company consolidate subsidiary refer bristolmyer squibb bms company context indicate term define annual report fiscal year end december libor london interbank offer rate abbvie abbvie inc lilly eli lilly company acute lymphoblastic leukemia loe loss exclusivity amgen amgen inc mcrc metastatic colorectal cancer amylin amylin pharmaceuticals inc mcrpc metastatic castrationresistant prostate cancer anda abbreviate new drug application mdl multidistrict litigation asean association southeast asian nations mead johnson mead johnson nutrition company astrazeneca astrazeneca plc merck merck inc biogen biogen inc myelofibrosis cardioxyl cardioxyl pharmaceuticals inc mpm malignant pleural mesothelioma comprehensive environmental response compensation cercla msih high microsatellite instability liability act celgene celgene corporation muc metastatic urothelial carcinoma chmp committee medicinal product human use nav net asset value cml chronic myeloid leukemia nektar nektar therapeutic cormorant cormorant pharmaceutical nitto denko nitto denko corporation cppib credit europe sarl luxembourg private limited liability cppib nkt natural killer company crc colorectal cancer novartis novartis pharmaceutical corporation cytomx cytomx therapeutics inc nsclc nonsmall cell lung cancer dmmr dna mismatch repair deficient nvaf nonvalvular atrial fibrillation dsa distribution service agreement ono ono pharmaceutical ltd european commission otc overthecounter ema european medicine agency otsuka otsuka pharmaceutical ltd epo european patent office pad proteinpeptidyl arginine deiminase ep earning share padlock padlock therapeutics inc erisa employee retirement income security act program death receptor european union pfizer pfizer inc fasb financial accounting standard board promedior promedior inc fcpa foreign corrupt practice act psa prostatespecific antigen fda food drug administration psioxus psioxus therapeutic ltd flexus flexus biosciences inc research development fstar fstar alpha ltd rheumatoid arthritis gaap generally accept accounting principle rcc renal cell carcinoma gilead gilead sciences inc reckitt reckitt benckiser group plc glaxosmithkline glaxosmithkline plc roche roche holding gtn grosstonet sanofi sanofi halozyme halozyme therapeutics inc sbla supplemental biologic license application hiv human immunodeficiency virus scchn squamous cell carcinoma head neck ifm ifm therapeutics inc sclc small cell lung cancer imclone imclone system incorporate sec securities exchange commission immunooncology biotek biotek ltd ipf idiopathic pulmonary fibrosis plan stock award incentive plan ipierian ipierian inc united states iprd inprocess research development united kingdom janssen janssen pharmaceuticals inc vte venous thromboembolic jia juvenile idiopathic arthritis bristolmyers squibb board directors giovanni caforio dinesh paliwal chairman board chief executive officer president chief executive officer bristolmyers squibb harman international peter arduini president chief executive officer theodore samuel integra lifescience holding corporation president capital guardian trust company robert bertolini president chief financial officer vicki sato phd bausch lomb chief financial officer lead independent director bristolmyers squibb scheringplough independent chairman board denali therapeutics inc professor management practice molecular cell biology harvard matthew emmens university chief executive officer chairman board shire plc president chief executive officer chairman vertex gerald storch pharmaceuticals chief executive officer chief executive officer storch advisor astra merck vice chairman target chairman chief executive officer toy principal mckinsey company michael grobstein vice chairman ernst young llp karen vousden phd chief scientist cancer research chief alan lacy executive officer beatson institute cancer trustee fidelity fund chairman research dave busters entertainment inc audit committee committee director corporate governance compensation management development committee science technology committee bristolmyer squibb leadership team giovanni caforio ann powell judge chairman board senior vice president chief executive officer chief human resource officer charle bancroft sandra leung executive vice president chief financial executive vice president officer global business operation general counsel paul biondi thomas lynch senior vice president executive vice president strategy business development chief scientific officer chris boerner phd lou schmukler executive vice president senior vice president president chief commercial officer global product development supply adam dubow paul von autenrie senior vice president senior vice president chief compliance ethic officer chief information officer john elicker senior vice president corporate affair investor relation bristolmyers squibb stockholder information common stock product name company program ticker symbol bmy free copy company annual global product company program new york stock exchange report fiscal year name appear italic end december contact refer register stockholder service approve trademark corporate secretary specifically note inquiry concern stockholder bristolmyer squibb company account stock transfer matter street abilify trademark otsuka include address change new york pharmaceutical ltd elimination duplicate mailing shareowner service plus plansm available adcetris trademark seattle direct companys investorbmscom genetics inc transfer agent registrar recent certification atripla truvada tybost trademark companys chief executive officer chief gilead sciences inc andor shareowner services financial officer pursuant section affiliate centre pointe curve suite sarbanesoxley act file mendota height exhibit company avaproavalide know company file new york aprovelkarvea plavix wwwshareowneronlinecom stock exchange recent annual trademark sanofi ceo certification require section byetta trademark amylin outside new york stock exchange pharmaceuticals llc list company manual telecommunication relay service enhanze trademark halozyme inc hear impair additional information call telephone number erbitux trademark imclone llc information follow subject farxiga onglyza trademark shareowner service plus plansm available wwwbmscom astrazeneca shareowner service plus plansm bristolmyers squibb foundation design longterm investor wish clinical trial gleevec trademark novartis build share ownership company compliance ethic ixempra trademark rpharm common stock time partici diversity workforce statistic operate llc pate plan register holder company common stock patient assistance program keytruda trademark merck sharp company common stock policy advocacy engagement dohme corp participant make political contribution prostvac trademark initial purchase plan plan sustainabilityenvironmental programs immunotherapeutics inc feature dividend reinvestment optional cash purchase share safekeepe annual report contain certain secure future trademark share sale transfer bristolmyer forwardlooke information bristolmyers squibb squibb company appoint share mean private security litigation brand name product owner service administrator plan reform act forwardlooke italicize letter asterisk plan sponsor administer statement base current expec register trademark bristolmyer bristolmyers squibb company tation involve inherent risk squibb andor subsidiary uncertainty cause actual come result differ materially current expectation financial review discussion description risk uncertainty company undertake obligation publicly update forwardlooke statement result new information future event shareowner service plus plan service mark shareowner services patient story wait breakthrough samantha wesson let disease stop live life full samantha wesson countless shortlived body patient wait breakthrough adapt reject treatment usually yearold wife mother year poughkeepsie new york samantha suffer psoriasis incurable autoimmune recently samantha develop disease skin cell build form painful joint pain associate scale itchy painful dry patch psoriatic arthritis psoriatic arthritis form arthritis pain knee ankle affect people psoriasis make difficult bed say cover head toe ugly painful itching pretty despite hardship devastating samantha say samantha endure samantha husband paul credit support remain positive optimistic like patient samantha develop family friend strength stay hopeful let disease control psoriasis age develop despite autoimmune disorder life say support psoriatic arthritis later life struggle age family friend unfortunately people society judge let stop live life full appearance psoriasis appear ear accord samantha progress new treatment option mean scalp say samantha young girl hope patient psoriasis symptom terribly embarrassing people think condition want thank work find breakthrough contagious say mean bring relief family wait hope new treatment samantha begin treat symptom cream work medication little effect disease progress turn treatment include biologics bristolmyers squibb recently enrol phase clinical trial provide relief break suffer tyk inhibitor psoriasis bristolmyer squibb company right reservedbmscom bristolmyer squibb bmsnews bristolmyers squibb bristolmyers squibb street new york troper launna bbiuqs sreymlotsirb